Bluebirdbio stock.

04:04 PM ET 08/09/2021. Bluebird Bio ( BLUE) said Monday the Food and Drug Administration paused one of its gene therapy studies due to safety concerns, and BLUE stock collapsed. The drug isn't ...

Bluebirdbio stock. Things To Know About Bluebirdbio stock.

According to 9 stock analysts, the average 12-month stock price forecast for bluebird bio stock is $7.91, which predicts an increase of 107.07%. The lowest target is $3.00 and the highest is $13. On average, analysts rate bluebird bio stock as a buy.According to the issued ratings of 12 analysts in the last year, the consensus rating for bluebird bio stock is Hold based on the current 1 sell rating, 5 hold ratings and 6 buy ratings for BLUE. The average twelve-month price prediction for bluebird bio is $7.62 with a high price target of $13.00 and a low price target of $3.00. Learn more on ...Bluebird Bio could soon earn approval for two key gene-editing therapies. However, the company does face severe financial troubles. Bluebird's stock is risky, but the rewards could be huge. Motley ...One particular, let's check out Bluebird. Shares of Bluebird Bio, ticker symbol BLUE, now, you're seeing that move lower by about 11.3%. This is after the Food and Drug Administration approved the ...

When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...When picking the best stocks under $10 to buy, it's important to identify fundamentally strong and non-speculative stocks. These are fundamentally strong and non-speculative stocks that are under $10 Since the meme stock euphoria in 2020, i...Mar 10, 2022 · Shares of Bluebird Bio ( BLUE 0.61%) were sinking 10.4% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence. The decline came after the company ...

Bluebird Bio (BLUE 11.52%) and CRISPR Therapeutics (CRSP 2.88%) are two rising biotechs that specialize in gene-editing therapies to treat rare genetic blood disorders and cancer.

- Commercial launch of ZYNTEGLO® (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 -- Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash - SOMERVILLE, Mass.--(BUSINESS WIRE)--Nov. 7, 2022-- bluebird …What happened. Shares of the gene therapy pioneer Bluebird Bio ( BLUE -1.04%) have been under heavy pressure this week. The biotech's stock dropped by a noteworthy 28.8% during the first three and ...Bluebird bio seeks FDA priority review for sickle cell disease therapy lovo-cel Apr. 24, 2023 7:55 AM ET bluebird bio, Inc. (BLUE) VRTX , CRSP By: Dulan Lokuwithana , SA News Editor 15 Comments ...Shares of bluebird bio BLUE have increased by 25.6% in a month compared with the industry ’s growth of 0.2%. Last month, bluebird posted better-than-expected results in the third quarter. It ...The bluebird bio stock price gained 3.74% on the last trading day (Thursday, 2nd Nov 2023), rising from $2.94 to $3.05. During the last trading day the stock fluctuated 7.02% from a day low at $2.92 to a day high of $3.13. The price has risen in 7 of the last 10 days and is up by 9.71% over the past 2 weeks. Volume has increased on the …

bluebird bio, Inc. Common Stock (BLUE) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

Trading bluebird bio to $6: Bluebird bio (BLUE) is a biotech company focused on developing and commercializing gene and cell therapies to treat genetic diseases. Lead asset LentiGlobin (Zynteglo) is approved in US and Europe for the treatment of transfusion-dependent thalassemia. Bluebird's LentiGlobin (lovo-cel) is also in prBluebird bio (BLUE ...

What happened. Shares of gene therapy company Bluebird Bio ( BLUE -6.90%) fell by 10.7% through the first four full days of trading this week, according to data provided by S&P Global Market ...With its shares down by around 84% in the past year, it's a wonder that investors are still interested in Bluebird Bio ( BLUE -4.44%) at all. It withdrew its beta thalassemia drug, Zynteglo, from ...See the latest bluebird bio Inc stock price (BLUE:XNAS), related news, valuation, dividends and more to help you make your investing decisions.bluebird bio, Inc. is a clinical-stage biotechnology company ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.- Commercial launch of ZYNTEGLO® (betibeglogene autotemcel) underway; on track for first apheresis in the fourth quarter of 2022 -- Chris Krawtschuk appointed chief financial officer - - Ended quarter with $186M in cash and cash equivalents, marketable securities and restricted cash - SOMERVILLE, Mass.--(BUSINESS WIRE)--Nov. 7, 2022-- bluebird …

SCD (HGB-206) bluebird bio, Inc. gene therapy for sickle cell disease is investigational and not FDA-approved. Safety and efficacy have not been established. View the bluebird bio development pipeline and explore our list of gene therapy products and candidates at all development phases.SOMERVILLE, Mass.--(BUSINESS WIRE)--Aug. 8, 2023-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the second quarter ended June 30, 2023, including recent commercial and operational progress, and regulatory updates.bluebird bio stock forecasts are adjusted once a day based on the closing price of the previous trading day. The minimum target price for bluebird bio analysts is $ 7.2. Today 200 Day Moving Average is the resistance level (3.733 $). 50 Day Moving Average is the support level (3.087 $).With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.AnaptysBio Inc. 14.20. UNCH. UNCH. Get bluebird bio Inc (BLUE:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.bluebird bio, Inc. Common Stock (BLUE) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.

Bluebird bio Inc’s current trading price is -47.49% away from its 52-week high, while its distance from the 52-week low is 78.77%. The stock’s price range over this period has fluctuated between $2.52 and $8.58. The company, operating within the financial sector, had a trading volume of approximately 2.61 million for the day, which was ...Nov 8, 2021 · Shares of Bluebird Bio ( BLUE 2.64%) were plunging 19.3% lower as of 3:42 p.m. EST on Monday. The sharp decline came after two analysts downgraded Bluebird. Goldman Sachs ( GS 0.15%) analyst ...

bluebird bio. bluebird bio received FDA accelerated approval for SKYSONA® (elivaldogene autotemcel) gene therapy for early, active cerebral adrenoleukodystrophy (CALD). SKYSONA is the first FDA approved therapy shown to slow the progression of neurologic dysfunction in boys with this devastating and fatal neurodegenerative disease.24 thg 10, 2023 ... Yes, a replay of the webcast will be available on the bluebird website for 90 days following the event. Stock BLUE logo.It takes a lot of money to launch gene therapies, and CRISPR has a much bigger war chest than Bluebird Bio. As of Sept. 30, the company had $1.973 billion in cash while Bluebird, even after ...bluebird bio, Inc. analysts consensus, targets, ratings and recommendations | London Stock Exchange: 0HOH | London Stock ExchangeBluebird Bio has a market capitalization of around $425 million at the moment, so this small-cap biotech stock could see a significant increase in its share …Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower Monday. The stock initially surged in premarket trading following the U.S. Food and Drug Administration's accelerated approval of ...

Discover historical prices for BLUE stock on Yahoo Finance. View daily, weekly or monthly format back to when bluebird bio, Inc. stock was issued.

1. Bluebird Bio. Bluebird Bio is a biotech that seeks to develop gene-editing treatments for rare illnesses. Some of the company's efforts came to fruition this year as it finally earned U.S ...

bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders. The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. Dec 1, 2023 · 12 analysts have issued 1-year price objectives for bluebird bio's shares. Their BLUE share price targets range from $3.00 to $13.00. On average, they expect the company's share price to reach $7.62 in the next twelve months. This suggests a possible upside of 95.9% from the stock's current price. [email protected]. Investor Contacts. Courtney O’Leary. Investor Relations (978) 621-7347. [email protected]. stock quote stock sub menu. Stock Quote; Stock Chart (Common Stock) Exchange (US Dollar) Price: Change (%) Volume: Today's Open: Previous Close: Intraday High: Intraday Low:As at March 2023, bluebird bio had cash of US$318m and no debt. In the last year, its cash burn was US$328m. Therefore, from March 2023 it had roughly 12 months of cash runway. To be frank, this ...Get the latest bluebird bio, Inc. (BLUE) stock news and headlines to help you in your trading and investing decisions.Bluebird Bio has a market capitalization of around $425 million at the moment, so this small-cap biotech stock could see a significant increase in its share …Pgiam/iStock via Getty Images. bluebird bio ( NASDAQ: BLUE) added ~8% pre-market Wednesday after Bank of America upgraded the stock to Buy from Neutral, citing a potential FDA approval for its new ...Gene therapy developer bluebird bio ( NASDAQ: BLUE) announced an agreement with Jefferies on Tuesday to sell shares of the company's common stock to raise $125M in gross proceeds. The transaction ...

Shares of Bluebird Bio ( BLUE -3.00%) were plunging 22.3% as of 10:41 a.m. ET on Monday. The big drop came after the company announced that the Food and Drug Administration (FDA) placed its ...10 stocks we like better than Bluebird Bio When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has ...A high-level overview of bluebird bio, Inc. (BLUE) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Why Bluebird Bio Stock Soared 7% Higher on Tuesday Motley Fool - Tue Nov 7, 4:18PM CST . The company posted some encouraging numbers and said it had sufficient resources to take care of financial obligations through the second quarter of 2024. BLUE: 2.98 (-1.81%)Instagram:https://instagram. dell trading computergahcarcc dividendbest crypto trading course Discover historical prices for BLUE stock on Yahoo Finance. View daily, weekly or monthly format back to when bluebird bio, Inc. stock was issued. Find the latest 2seventy bio, Inc. (TSVT) stock quote, history, news and other vital information to help you with your stock trading and investing. qqq dividend yieldputnam investments login 24 thg 10, 2023 ... Yes, a replay of the webcast will be available on the bluebird website for 90 days following the event. Stock BLUE logo. tmf etf price Bluebird Bio has a market capitalization of around $425 million at the moment, so this small-cap biotech stock could see a significant increase in its share price if it lands this historic approval.Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...In the second quarter, it reported revenue of just $6.9 million, an improvement over the $1.5 million recorded in the year-ago period. Bluebird was also unprofitable, with a net loss of $0.67 per ...